Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Wants to Increase Safety Staffers to 270 by FY2023: Official
June 21, 2018
- Public Insurance Should Cover Pricy Drugs, Rather than Cold Medicines: MHLW’s Top MD Bureaucrat
June 21, 2018
- PMDA Slips to Second in Time-to-Approval Ranking
June 21, 2018
- LDP’s Pharma Study Group to Form Panel for Patch Medications, Proposal Due Out This Autumn
June 20, 2018
- PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
- Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing
June 18, 2018
- Authorized Generics for Aimix, Cravit IV Join NHI Price List
June 15, 2018
- Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
June 14, 2018
- Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
- Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
- LDP’s Eto Study Group Submits Proposal to Health Minister
June 13, 2018
- PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
June 13, 2018
- MHLW to Study Ways to Increase Transparency of Process for Including Vaccines in Public Vaccination Programs
June 12, 2018
- MHLW’s New Anti-RA Measures Likely to Push Proper Use of Pricy Biologics
June 11, 2018
- MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
- Further Price Cuts for Off-Patent Drugs Erased from Draft Honebuto Paper
June 11, 2018
- Panel Members Positive about Going Digital on Package Inserts: HSC
June 11, 2018
- Govt Should Screen Drug Promotion Material, Scope of Information Provided: HSC Member
June 8, 2018
- Experts Support Plan to Seize Improperly Earned Revenue as in Diovan Case: HSC
June 8, 2018
- AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…